GLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD)
Study Details
Study Description
Brief Summary
Cerebral small vessel disease (cSVD), a result of neurovascular cell dysfunction, is a major cause of stroke, dementia and mobility problems worldwide. Vascular risk factor control alone may not be sufficient to prevent the development of vascular cognitive impairment (VCI) in patients with cSVD according to previous clinical trials.
The presence of glucagon-like peptide-1 receptor (GLP-1R) in cerebral microglia may reveal a potential therapeutic target for prevention of cSVD progression and its disabling clinical outcomes. At the cellular and animal experimentation levels, GLP-1R agonist demonstrated reversal of some pathogenic processes in cSVD. However, its application to cSVD patients remains to be elucidated.
Investigator aims to investigate the safety and efficacy of GLP-1R agonist in patients with moderate-to-severe cSVD.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Detailed Description
In this single-center, open-label (assessor blinded), randomized controlled study, 110 patients with cSVD of Age-Related White Matter Changes Scale of 2 or 3 will be randomized into "treatment arm" with GLP-1R agonist and standard medical therapy, and "control" arm with standard medical therapy alone in a 1:1 ratio. In this 78 weeks pilot study, investigators shall evaluate the tolerability and safety profile of exenatide, a GLP-1R agonist in SVD patients, together with changes in clinical, imaging and sonographic parameters.
Clinical and biochemical measures will be assessed at baseline, 12 weeks, 26 weeks and 52 weeks. Transcranial Doppler Ultrasound (TCD) will be performed at baseline, 12 weeks, 26 weeks, 52 weeks and 78 weeks. MRI will be performed at baseline and 78 weeks
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Active Comparator: Exenatide extended release Prescribe study drug: Exenatide extended release. The dosage and frequency is 2mg once weekly via subcutaneous injection for 78 weeks |
Drug: Exenatide extended release
2mg once weekly via subcutaneous injection
Other Names:
|
| No Intervention: Standard of care Standard medical therapy |
Outcome Measures
Primary Outcome Measures
- Change of Brain Peak Width of Skeletonized Mean Diffusivity [Baseline and week 78]
Peak Width of Skeletonized Mean Diffusivity is a robust, fully-automated and easy-to-implement marker for cerebral small vessel disease based on diffusion tensor imaging, white matter tract skeletonization and histogram analysis. It is a biomarker for brain MRI images.
Secondary Outcome Measures
- Number of recurrent stroke [Baseline and week 78]
Record of any recurrent stroke from medical note/system
- Change of Hong Kong MOntreal Cognitive Assessment [Baseline, week 12, week 26, week 52 and week 78]
Hong Kong MOntreal Cognitive Assessment (HK-MoCA) is a cognitive assessment tool. Score from 0 to 30 . The lower score reflect the worse the outcome.
- Change The Chinese Geriatric Depression Scale 30 [Baseline, week 12, week 26, week 52 and week 78]
The Chinese Geriatric Depression Scale is used to detect depressive mood. Score 0 to 30. The higher the score, the worse the outcome
- Change of Pittsburgh sleep quality index [Baseline, week 12, week 26, week 52 and week 78]
Pittsburgh sleep quality index Chinese Version is a self-report questionnaire that assesses sleep quality over a 1-month time interval. The questionnaire contains frequency questions related to sleep quality, each question scale from 0 to 3. The higher the score, the worse the outcome. There is no total score available for this assessment
- Change of Hong Kong List Learning Test [Baseline, week 12, week 26, week 52 and week 78]
Hong Kong List Learning Test s a newly developed Chinese memory test designed for the assessment of the processes and organizational strategies involved in learning verbal information. The more negative the standard deviation the worse the outcome
- Change of Neuropsychiatric Inventory [Baseline, week 12, week 26, week 52 and week 78]
Neuropsychiatric Inventory is a brief interview with a family member or friend who knows the study subject . It is used to measure behavioral symptoms. It evaluates 12 behavioral areas commonly affected in patients with dementia. It evaluates the frequency (scale from 1 to 4), severity (scale from 1 to 3), distress to caretaker (scale from 1 to 5) of each behavioral symptom. The higher the score of any area means the worse outcome. There is no total score available for this assessment
- Change of disability assessment for dementia [Baseline, week 12, week 26, week 52 and week 78]
Disability assessment for dementia evaluates 11 basic daily activities of elderly people with dementia. It evaluates each activity in 3 stages: initiation, planning and organization, effective performance. Score 1 or 0 for each question. The higher the total score, the better the outcome. The total score is from 0 to 47.
- Change of Gait [Baseline, week 12, week 26, week 52 and week 78]
Gait velocity will be assessed using the 8-meter walking time. Time for walking 8-m will be measured by a stopwatch. The faster of two trials will be used in the analysis The faster of the walking time the better outcome.
- Change of balance [Baseline, week 12, week 26, week 52 and week 78]
Single leg stance time will be measured by asking individuals, with their hands on their hips, to balance as long as possible on one leg with an upper limit of 30 seconds. Two trials for each leg will be performed. The best time of the four trials will be used for analysis. The longer to time duration the better outcome.
- Change of Pulsatility Index [Baseline, week 12, week 26, week 52 and week 78]
Pulsatility Index of Transcranial doppler ultrasound is a painless test that uses sound waves to detect medical problems that affect blood flow in your brain. It is a measure of vascular resistance of cerebral vessels. The higher the index means higher resistance and stiffness of blood vessels which lead to worse outcome. There is no minimum or maximum values available for this index.
- Change of Breath Holding Index [Baseline, week 12, week 26, week 52 and week 78]
Breath Holding Index calculated based on the mean flow velocities of the middle cerebral artery using transcranial Doppler. It indicates the brain artery could react better to lowered oxygen level. The higher the index means better reaction to lowered oxygen level which leads to better outcome. There is no minimum or maximum values available for this index.
- Change of DNA methylation [Baseline, week 12, week 26, week 52 and week 78]
blood biomarker. DNA methylation-derived epigenetic age clock is an indicator of biological aging.
- Change of neurovascular inflammation [Baseline, week 12, week 26, week 52 and week 78]
blood biomarker to investigate neurovascular inflammation that induce neurodegeneration
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Chinese ethnicity;
-
Age 55 to 80 years old;
-
Age-Related White Matter Change (ARWMC) Scale of 2 or early 3 in FLAIR MRI;
-
Modified Functional Ambulation Classification 5 or above;
-
Montreal Cognitive Assessment (MoCA) score < 25;
-
Both diabetic and non-diabetic patient are eligible;
-
Patient who understands the purpose and requirements of the study, and able to provide an informed consent;
Exclusion Criteria:
-
Dementia or MoCA score lower than 2nd percentile of the age and education adjusted cutoff ;
-
Cerebral white matter changes unrelated to neurodegenerative, e.g. CADASIL, X-linked adrenoleukodystrophy, metabolic diseases, multiple sclerosis, etc.;
-
Contraindication to GLP-1R agonist, including thyroid carcinoma, pancreatic pathology, proliferative retinopathy, hypersensitivity to GLP-1R agonist and history of family history of multiple endocrine neoplasia;
-
BMI <18.5kg/m2;
-
Contraindication to proposed imaging, e.g. chronic kidney disease (KDNIGO) stage 4 or above, acute kidney injury, hypersensitivity to gadolinium-based contrast, non-MRI conditional implants or prosthesis;
-
Medical condition that would not allow the patient to adhere to the protocol or complete the study.;
-
Patient with established neurodegenerative disorders (e.g. Parkinson's Disease, Alzheimer's Disease, etc.);
-
Pregnancy.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Chinese University of Hong Kong | Hong Kong | Hong Kong |
Sponsors and Collaborators
- Chinese University of Hong Kong
Investigators
- Principal Investigator: Bonaventure Yiu Ming Ip, MBChB, Chinese University of Hong Kong
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- GAPP-SVD